The use of autologous mesenchymal stem cells in complications of diabetes mellitus, in particular diabetic retinopathy: inputs and insights

Manshuk Yeltokova 1, Zeinet Аkhmedyanova 2, Zhanna Bayanbayeva 2 * , Assel Khassenova 3, Kulchat Yermekova 2
More Detail
1 Department of Ophthalmology, National Scientific Medical Center, Astana, Kazakhstan
2 Department of Eye Diseases, Astana Medical University, Astana, Kazakhstan
3 Department of Academic Quality Unit, School of Public Health, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 19, Issue 2, pp. 9-13.
OPEN ACCESS 535 Views 346 Downloads
Download Full Text (PDF)


The review provided reveals the analysis of the available scientific literature on the feasibility of using cellular technologies, such as, autologous mesenchymal stem cells (MSCs) for diabetic retinopathy treatment. The results indicated the viability of cellular technologies in clinical ophthalmology with respect to anatomical features and immune privilege of the organ of vision. Additionally, feasibility, safety, and optimization of pathogenetic therapy for MSC transplantation expands the prospect of their use in late complications of type 1 and type 2 diabetes mellitus, in particular, diabetic retinopathy.


Yeltokova M, Аkhmedyanova Z, Bayanbayeva Z, Khassenova A, Yermekova K. The use of autologous mesenchymal stem cells in complications of diabetes mellitus, in particular diabetic retinopathy: inputs and insights. J CLIN MED KAZ. 2022;19(2):9-13.


  • Öner A. Stem Cell Treatment in Retinal Diseases: Recent Developments. Turk J Ophthalmol. 2018;48:33-38.
  • Harrell CR, Fellabaum C, Arsenijevic A, Markovic BS, Djonov V, Volarevic V. Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of Glaucoma. Stem Cells Int. 2019; 2019:7869130.
  • Blenkinsop TA, Corneo B, TempleS, Stern JN. Ophthalmologic stem cell transplantation therapies. Regen Med. 2012; 7(6):32-9.
  • Baddour JA, Sousounis K, Tsonis PA. Organ repair and regeneration: an overview. Birth Defects Res C Embryo Today. 2012;96:1-29.
  • Lo Furno D, Mannino G, Giuffrida R, Gili E, Vancheri C, Tarico MS, Perrotta RE, Pellitteri R. Neural differentiation of human adipose-derived mesenchymal stem cells induced by glial cell conditioned media. J Cell Physiol. 2018;233:7091-7100.
  • Hu ZL, Li N, Wei X, Tang L, Wang TH, Chen XM. Neuroprotective effects of BDNF and GDNF in intravitreally transplanted mesenchymal stem cells after optic nerve crush in mice. Int J Ophthalmol. 2017;10(1):35-42.
  • Li, T., Xia, M., Gao, Y., Chen, Y., and Xu, Y. Human umbilical cord mesenchymal stem cells: an overview of their potential in cell-based therapy. Expert Opin. Biol. Ther. 2015; 1293–1306.
  • Streilein JW. Ocular immune privilege therapeutic opportunities from an experiment of nature. Nat. Rev. Immunol. 2003; 3 (II):879-889.|nri1224
  • Ryan, J. M., Barry, F. P., Murphy, J. M., and Mahon, B. P. Mesenchymal stem cells avoid allogeneic rejection. J. Inflamm. 2005; 2:8.
  • Ding, S. L. S., Kumar, S., and Mok, P. L. Cellular reparative mechanisms of mesenchymal stem cells for retinal diseases. Int. J. Mol. Sci. 2017; 18:1406.
  • Mannino G, Russo C, Longo A, Anfuso CD, Lupo G, Lo Furno D, Giuffrida R, Giurdanella G. Potential therapeutic applications of mesenchymal stem cells for the treatment of eye diseases. World J Stem Cells. 2021; 13(6):632-644
  • Scholl, H. P., Strauss, R. W., Singh, M. S., Dalkara, D., Roska, B., Picaud, S., et al. Emerging therapies for inherited retinal degeneration. Sci. Transl. Med. 2016; 8:368rv366.
  • Veleri, S., Lazar, C. H., Chang, B., Sieving, P. A., Banin, E., and Swaroop, A. Biology and therapy of inherited retinal degenerative disease: insights from mouse models. Dis. Model. Mech. 2015; 8:109–129.
  • Mead, B., Hill, L. J., Blanch, R. J., Ward, K., Logan, A., Berry, M., et al. Mesenchymal stromal cell-mediated neuroprotection and functional preservation of retinal ganglion cells in a rodent model of glaucoma. Cytotherapy. 2016; 18:487–496.
  • Rashid, K., Wolf, A., and Langmann, T. Microglia activation and immunomodulatory therapies for retinal degenerations. Front. Cell. Neurosci. 2018; 12:176.
  • Ghosh, F., Abdshill, H., Arner, K., Voss, U., and Taylor, L. Retinal neuroinflammatory induced neuronal degeneration - role of toll-like receptor-4 and relationship with gliosis. Exp. EyeRes. 2018; 169:99–110.
  • Dalkara, D., Goureau, O., Marazova, K., and Sahel, J. A. Let there be light: gene and cell therapy for blindness. Hum. Gene Ther. 2016; 27:134–147.
  • Oswald, J., and Baranov, P. Regenerative medicine in the retina: from stem cells to cell replacement therapy. Ther. Adv. Ophthalmol. 2018; 10:2515841418774433.
  • Ferrara, N., and Adamis, A. P. Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov. 2016; 15:385–403.
  • Mansoor, H., Ong, H. S., Riau, A. K., Stanzel, T. P., Mehta, J. S., & Yam, G. H. F. Current Trends and Future Perspective of Mesenchymal Stem Cells and Exosomes in Corneal Diseases. International Journal of Molecular Sciences. 2019; 20(12):ARTN 2853.
  • Zhang, W., Wang, Y., Kong, J. et al. Therapeutic efficacy of neural stem cells originating from umbilical cord-derived mesenchymal stem cells in diabetic retinopathy. Sci Rep. 2017; 7:408.
  • Rajashekhar, G., Ramadan, A., Abburi, C., Callaghan, B., Traktuev, D. O., Evans-Molina, C., Maturi, R., Harris, A., Kern, T. S., & March, K. L. Regenerative Therapeutic Potential of Adipose Stromal Cells in Early Stage DiabeticRetinopathy. PlosOne. 2014; 9(1):ARTNe84671.
  • Arden, G. B. &Sivaprasad, S. The pathogenesis of early retinal changes of diabetic retinopathy. Doc Ophthalmol. 2012;124(1):15-26.
  • Si, Y. L., Zhao, Y. L., Hao, H. J., Fu, X. B. & Han, W. D. MSCs: biological characteristics, clinical applications and their outstanding concerns. Ageing Res Rev. 2011;10(1):93-103.
  • Do D V., Nguyen QD, Vitti R, Berliner AJ, Gibson A, Saroj N, Soo Y, Boyer DS: Intravitrealaflibercept injection in diabetic macular edema patients with and without prior anti-vascular endothelial growth factor treatment outcomes from the phase 3 program. Ophthalmology. 2016;123(4):850-7.
  • Falavarjani KG, Nguyen QD Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013; 27(7):787-94.
  • Adak, S., Magdalene, D., Deshmukh, S. et al. A Review on Mesenchymal Stem Cells for Treatment of Retinal Diseases. Stem Cell Rev and Rep. 2021; 17:1154–1173.
  • Bazzazi, H., Zhang, Y., Jafarnejad, M., Isenberg, J. S., Annex, B. H., &Popel, A. S. Computer simulation of TSP1 inhibition of VEGF-Akt-eNOS: An angiogenesis triple threat. FrontiersinPhysiology. 2018; 9:1–14.
  • Ghazaryan, E., Zhang, Y., He, Y., Liu, X., Li, Y., Xie, J., & Su, G. Mesenchymal stem cells in corneal neovascularization: Comparison of different application routes. Molecular Medicine Reports. 2016.
  • Fiori A, Hammes HP, Bieback K. Adipose-derived mesenchymal stromal cells reverse high glucose-induced reduction of angiogenesis in human retinal microvascular endothelial cells. Cytotherapy. 2020; 22:261-275
  • Li Y, He X, Li J, Ni F, Sun Q, Zhou Y. Proliferation and differentiation of direct co‑culture of bone marrow mesenchymal stem cells and pigmented cells from the ciliary margin. Mol Med Rep. 2017;15(6):3529-3534.
  • Safwat, A., Sabry, D., Ragiae, A., Amer, E., Mahmoud, R. H., &Shamardan, R. M. Adipose mesenchymal stem cells–derived exosomes attenuate retina degeneration of streptozotocin-induced diabetes in rabbits. JournalofCirculatingBiomarkers. 2018; 7:1–10.
  • Feng, Y., Zhu, R., Shen, J., Wu, J., Lu, W., Zhang, J., Zhang, J., & Liu, K. Human Bone Marrow Mesenchymal Stem Cells Rescue Endothelial Cells Experiencing Chemotherapy Stress by Mitochondrial Transfer Via Tunneling Nanotubes. StemCellsandDevelopment. 2019.
  • Eells, J. T. Mitochondrial dysfunction in the aging retina. Biology. 2019.
  • Bhattacharya S, Gangaraju R, Chaum E. Recent Advances in Retinal Stem Cell Therapy. Curr Mol Biol Rep. 2017;3(3):172-182.
  • NIH Facts AboutDIabetic. [(accessed on 7 July 2019)];2015 Available online:
  • Baek SJ, Kang SK, Ra JC. In vitro migration capacity of human adipose tissue-derived mesenchymal stem cells reflects their expression of receptors for chemokines and growth factors. Exp Mol Med. 2011;43(10):596-603.
  • Bhattacharya S, Gangaraju R, Chaum E. Recent Advances in Retinal Stem Cell Therapy. Curr Mol Biol Rep. 2017;3(3):172-182.
  • Nirwan RS, Albini TA, Sridhar J, Flynn HW Jr, Kuriyan AE. Assessing "Cell Therapy" Clinics Offering Treatments of Ocular Conditions using Direct-to-Consumer Marketing Websites in the United States. Ophthalmology 2019;126:1350-5.
  • Yeltokova M, Ulyanova O, Askarov M, Chernyshova A, Kozina L. Integral Hematologic Indices in the Evaluation of the Immunologic Reactivity of the Organism in a Patient With Complication of Type 1 Diabetes Mellitus: A Case of Diabetic Retinopathy After Autologous Mesenchymal Stem Cell Transplant. Exp Clin Transplant. 2019;17(1):234-235.